{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:49:46Z","timestamp":1792068586797,"version":"4.4.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.diagmicrobio.2026.117588","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T20:19:52Z","timestamp":1785701992000},"page":"117588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Activity of Aztreonam-avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa causing infections in patients hospitalized in hematology, oncology, and transplant units from United States medical centres (2019-2024)"],"prefix":"10.1016","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":false,"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3702-1097","authenticated-orcid":false,"given":"Todd","family":"Riccobene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-1543","authenticated-orcid":false,"given":"John H.","family":"Kimbrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9976-7898","authenticated-orcid":false,"given":"Krisztina M.","family":"Papp-Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2026.117588_bib0001","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1001\/jama.2016.16477","article-title":"Prevalence of immunosuppression among US adults, 2013","volume":"316","author":"Harpaz","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117588_bib0002","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/cid\/ciaa190","article-title":"Risk factors for extended-spectrum beta-lactamase-producing enterobacterales bloodstream infection among solid-organ transplant recipients","volume":"72","author":"Anesi","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117588_bib0003","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jinf.2018.10.003","article-title":"Risk factors for mortality among carbapenem-resistant enterobacteriaceae carriers with focus on immunosuppression","volume":"78","author":"Bar-Yoseph","year":"2019","journal-title":"J Infect"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117588_bib0004","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jinf.2016.07.002","article-title":"Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies","volume":"73","author":"Satlin","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2026.117588_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious diseases society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117588_bib0006","article-title":"Effect of intravenous immunoglobulin on the function of treg cells derived from immunosuppressed mice with Pseudomonas aeruginosa pneumonia","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117588_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf005","article-title":"Frequency, antimicrobial susceptibility, and molecular characterization of carbapenem-resistant enterobacterales stratified by United States census divisions: results from the INFORM Program (2018-2022)","volume":"12","author":"Sader","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2026.117588_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106744","article-title":"Comparative activity of newer beta-lactam\/beta-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021)","volume":"61","author":"Sader","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2026.117588_bib0009","article-title":"M07Ed12. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","year":"2024","journal-title":"CLSI"},{"issue":"3","key":"10.1016\/j.diagmicrobio.2026.117588_bib0010","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2026.117588_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2026.107835","article-title":"Multidrug-resistant enterobacterales in United States hospitals: frequency and susceptibility to newer \u03b2-lactamase inhibitor combinations (2020\u20132024)","volume":"67","author":"Sader","year":"2026","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2026.117588_bib0012","series-title":"Performance standards for antimicrobial susceptibility testing; 35th informational supplement","article-title":"M100Ed35","year":"2025"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2026.117588_bib0013","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad038","article-title":"Trends of beta-lactamase occurrence among Escherichia coli and Klebsiella pneumoniae in United States hospitals during a 5-year period and activity of antimicrobial agents against isolates stratified by beta-lactamase type","volume":"10","author":"Castanheira","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2026.117588_bib0014","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cmb.2012.0021","article-title":"SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing","volume":"19","author":"Bankevich","year":"2012","journal-title":"J Comput Biol"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2026.117588_bib0015","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1186\/s12879-024-10133-5","article-title":"Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales","volume":"24","author":"Sader","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2026.117588_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics13060564","article-title":"Activity of aztreonam\/avibactam and recently approved beta-lactamase inhibitor combinations against Enterobacterales and Pseudomonas aeruginosa from intensive care unit and non-intensive care unit patients","volume":"13","author":"Sader","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.diagmicrobio.2026.117588_bib0017","article-title":"A 10-year trend of antimicrobial resistance in Pseudomonas aeruginosa from United States medical centers: results from the INFORM surveillance program (2015\u20132024)","volume":"67","author":"Sader","year":"2026","journal-title":"Int J Antimicrob Agents"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288932600338X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073288932600338X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:07:43Z","timestamp":1792066063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073288932600338X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S073288932600338X"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117588","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of Aztreonam-avibactam and Ceftazidime-Avibactam against Enterobacterales and Pseudomonas aeruginosa causing infections in patients hospitalized in hematology, oncology, and transplant units from United States medical centres (2019-2024)","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2026.117588","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117588"}}